This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
DARWIN EU data partners onboarded in phases I, II and III
Orphan designation: Elraglusib Treatment of pancreatic cancer, 16/01/2025 Positive
Orphan designation: Alvelestat Treatment of congenital alpha-1 antitrypsin defic...
Orphan designation: Camostat mesilate Treatment of chronic pancreatitis, 16/01/2...
Human medicines European public assessment report (EPAR): Saxenda, liraglutide, ...
Incyte is sticking to its strategy this year of finding “early-stage, exotic stu...
Ahead of a meeting with President Donald Trump, trade group the Pharmaceutical R...
Data Analysis and Real World Interrogation Network (DARWIN EU)
Human medicines European public assessment report (EPAR): Sapropterin Dipharma, ...
CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendsch...
DARWIN EU: Making health data count
Human medicines European public assessment report (EPAR): Yesintek, ustekinumab,...
The state of the biotech investing is dark. Here's one reason why.
DARWIN EU data partners onboarded in phases I and II
DARWIN EU Advisory Board meeting: 3 May 2024, Online, European Medicines Agency,...
Minutes - DARWIN EU Advisory Board - 3 May 2024
If the past teaches us anything, it is that no one should expect the government ...
Based on an Apple study, researchers have developed a free asthma management too...
The small but mighty Administration for Strategic Preparedness and Response at H...
How much weight loss is too much? Pharma is pushing the limit with new obesity d...
Human medicines European public assessment report (EPAR): Qaialdo, spironolacton...
Human medicines European public assessment report (EPAR): Memantine Mylan, meman...
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, D...
Ridgefield, Conn., and Ingelheim, Germany, Feb. 19, 2025 -- Boehringer Ingelheim...